

17

The method includes the step of administering Halofuginone, in a pharmaceutically acceptable carrier as described in Example 12 above, to a subject to be treated. Halofuginone is administered according to an effective dosing methodology, preferably until a predefined endpoint is reached, such as the absence of a particular tumor marker in a sample taken from the subject.

Examples of tumors for which such a treatment would be effective include, but are not limited to, breast cancers such as infiltrating duct carcinoma of the breast, lung, cancers such as small cell lung carcinoma, bone cancers, bladder cancers such as bladder carcinoma, rhabdomyosarcoma, angiosarcoma, adenocarcinoma of the colon, prostate or pancreas, squamous cell carcinoma of the cervix, ovarian cancer, malignant fibrous histiocytoma, skin cancers such as malignant melanoma, leiomyosarcoma, astrocytoma, glioma and hepatocellular carcinoma.

### EXAMPLE 13

#### Method of Manufacture of a Medicament Containing Halofuginone

The following is an example of a method of manufacturing Halofuginone. First, Halofuginone is synthesized in accordance with good pharmaceutical manufacturing practice. Examples of methods of synthesizing Halofuginone, and related quinazolinone derivatives, are given in U.S. Pat. No. 3,338,909. Next, Halofuginone is placed in a suitable pharmaceutical carrier, as described in Example 11 above, again in accordance with good pharmaceutical manufacturing practice.


While the invention has been described with respect to a limited number of embodiments, it will be appreciated that

18

many variations, modifications and other applications of the invention may be made.

What is claimed is:

1. A method for the treatment of a tumor sensitive to the compounds below in a subject, comprising the step of administering a pharmaceutically effective amount of a compound having a formula:



wherein:

R<sub>1</sub> is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;

R<sub>2</sub> is a member of the group consisting of hydroxy, acetoxy and lower alkoxy, and

R<sub>3</sub> is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl.

2. A method according to claim 1, wherein said compound is Halofuginone.

3. The method of claim 1, wherein the tumor is breast cancer, lung cancer, bladder cancer, bone cancer, prostate cancer, pancreas cancer, cervix cancer, ovarian cancer, skin cancer, or leiomyosarcoma cancer.

\* \* \* \* \*